Dr. Lydia Usha, Associate Professor of Medicine, Rush University Medical Center
Type of Research:
A Study of Folate Levels in Patients Treated with Olaparib
This is a study looking at folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib (Lynparza) to treat their advanced ovarian or breast cancer. The main goal of this study is to measure how often and when folate deficiency is most likely to occur; and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Folate deficiency can cause side effects and lead to reduction or stopping of treatment with olaparib.
The purpose of this study is to answer the following questions:
- What percentage of subjects develop folic acid deficiency after starting treatment with olaparib?
- How quickly does anemia develop after starting olaparib?
- For subjects who develop folic acid deficiency while on olaparib, does folic acid supplementation improve anemia, decrease the need for blood transfusions and allow subjects to stay on olaparib without needing to receive a smaller dose or stopping treatment?
- Does folic acid deficiency and folic acid supplementation impact the cancer response to olaparib?
- Why does folic acid deficiency occur in subjects treated with olaparib?
This clinical trial is currently open and enrolling. You can read more about who is eligible and how to enroll here.
Role of FORCE and ABOUT
FORCE will help with promotion and recruitment for the study.
This research is relevant for:
People diagnosed with breast cancer
People diagnosed with ovarian cancer
People in treatment